Skip to main content
. 2020 Dec 26;2(2):100140. doi: 10.1016/j.jtocrr.2020.100140

Figure 1.

Figure 1

Kaplan-Meier survival curve of progression-free survival in patients with nonsquamous NSCLC with Kras mutations who received ICIs. Differences in progression-free survival between patients with Kras-G12C and Kras-non-G12C were statistically significant (G12C [4.8 mo] versus non-G12C [2.1 mo], p = 0.028, by the log-rank test). ICI, immune checkpoint inhibitor.